<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6985">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966641</url>
  </required_header>
  <id_info>
    <org_study_id>PL-NAP-001</org_study_id>
    <secondary_id>NIH Grant 1R44AR056529-01</secondary_id>
    <nct_id>NCT00966641</nct_id>
  </id_info>
  <brief_title>Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults</brief_title>
  <official_title>&quot;A Single-Dose Crossover Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adult Volunteers in the Fasted State&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PLx Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>PLx Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the single-dose pharmacokinetics of the
      investigational drug PL 3100 following oral administration to healthy volunteers and to
      compare the pharmacokinetic profiles of PL 3100 and naproxen at a prescription dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area Under the Curve of Plasma Naproxen From 0 to t</measure>
    <time_frame>30 minutes prior to administration; 30, 60, and 90 minutes post drug administration; and 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, and 48 hours post drug administration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for evaluation of PK variables were collected over a 48-hour period after drug administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>PL 3100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active experimental drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Single orally administered dose of 500 mg naproxen</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL 3100</intervention_name>
    <description>Single orally administered dose of PL 3100 (500 mg naproxen)</description>
    <arm_group_label>PL 3100</arm_group_label>
    <other_name>Naproxen-PC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years, inclusive.

          -  Subject has a Body Mass Index (BMI) between 20 and 32, inclusive.

          -  Normal physical examination as determined by the Investigator.

          -  Normal clinical laboratory test results or clinically insignificant results as
             determined by the Investigator during the screening visit.

          -  If female and of child-bearing potential, the subject must have a negative pregnancy
             test and is not nursing.

          -  If female and of child-bearing potential, the subject must agree to use adequate
             birth control for the duration of the study.

        Exclusion Criteria:

          -  Subject has a history of chronic alcohol consumption or abuse of narcotics or
             alcohol.

          -  Subject has had an acute illness within 5 days of study medication administration.

          -  Subject is currently participating, or has participated within 30 days prior to study
             entry, in an investigational drug study.

          -  Subject has hypersensitivity or contraindications to naproxen, ibuprofen, or other
             NSAID.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Upendra K. Marathi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PLx Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 6, 2015</lastchanged_date>
  <firstreceived_date>August 25, 2009</firstreceived_date>
  <firstreceived_results_date>June 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PL3100 First, Then Naproxen</title>
          <description>First Intervention Period:
PL3100 Capsules: Single orally administered dose of PL 3100 (500 mg naproxen)
(after 7-14 day washout period)
Second Intervention Period:
Naproxen: Single orally administered dose of 500 mg naproxen</description>
        </group>
        <group group_id="P2">
          <title>Naproxen First, Then PL3100</title>
          <description>First Intervention Period:
Naproxen: Single orally administered dose of 500 mg naproxen
(after 7-14 day washout period)
Second Intervention Period:
PL3100 Capsules: Single orally administered dose of PL 3100 (500 mg naproxen)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants who were enrolled in the study.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38.2" spread="12.43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve of Plasma Naproxen From 0 to t</title>
        <description>Blood samples for evaluation of PK variables were collected over a 48-hour period after drug administration.</description>
        <time_frame>30 minutes prior to administration; 30, 60, and 90 minutes post drug administration; and 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, and 48 hours post drug administration.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) Evaluable Population consists of the 28 subjects who completed the study with no protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PL 3100</title>
            <description>Active experimental drug
PL 3100: Single orally administered dose of PL 3100 (500 mg naproxen)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Active comparator
Naproxen: Single orally administered dose of 500 mg naproxen</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve of Plasma Naproxen From 0 to t</title>
            <description>Blood samples for evaluation of PK variables were collected over a 48-hour period after drug administration.</description>
            <units>min×μg/mL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67763.0" lower_limit="38832.6" upper_limit="100019.6"/>
                  <measurement group_id="O2" value="69427.9" lower_limit="39529.0" upper_limit="93963.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PL 3100</title>
          <description>Active experimental drug
PL 3100: Single orally administered dose of PL 3100 (500 mg naproxen)</description>
        </group>
        <group group_id="E2">
          <title>Naproxen</title>
          <description>Active comparator
Naproxen: Single orally administered dose of 500 mg naproxen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Standard Confidentiality Agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Zimmerman</name_or_title>
      <organization>PLx Pharma</organization>
      <phone>1-713-842-1249 ext 205</phone>
      <email>ron.zimmerman@plxpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
